Table 2 Univariate Cox analyses predicting PFS and OS of corticosteroid switch
| Â | N | PFS, months | OS, months | ||||
|---|---|---|---|---|---|---|---|
Median (95%CI) | HR (95%CI) | p value | Median (95%CI) | HR (95%CI) | p value | ||
Age at corticosteroid switch, years | 1.17 (0.70–1.98) | 0.563 | |||||
  ≥ 70 | 81 | 5.5 (4.4–6.6) | 0.75 (0.51–1.10) | 0.139 | 18.1 (16.7–19.5) | ||
  < 70 | 49 | 3.2 (0.7–5.7) |  |  | 23.5 (13.5–33.5) | ||
ISUP grading at diagnosis | 0.89 (0.51–1.55) | 0.670 | |||||
  > 4 | 75 | 4.8 (3.5–6.1) | 1.01 (0.67–1.53) | 0.946 | 20.1 (14.3–25.9) | ||
  ≤ 4 | 43 | 5.5 (2.9–8.1) |  |  | 17.3 (13.4–21.2) | ||
ECOG at corticosteroid switch | 0.58 (0.34–0.97) | 0.037 | |||||
 0 | 76 | 5.6 (4.2–7.0) | 0.75 (0.51–1.10) | 0.140 | 23.5 (17.3–29.7) | ||
  ≥ 1 | 54 | 3.7 (2.2–5.2) |  |  | 17.4 (13.8–21.0) | ||
PSA at diagnosis, ng/mL | 1.01 (0.58–176) | 0.978 | |||||
  ≥ 100 | 76 | 4.8 (3.7–5.9) | 1.09 (0.71–1.65) | 0.703 | 19.0 (14.2–23.8) | ||
  < 100 | 41 | 5.9 (5.0–6.8) |  |  | 18.1 (14.2–22.0) | ||
PSA at corticosteroid switch, ng/mL | 0.37 (0.21–0.54) | < 0.001 | |||||
  ≤ 20 | 64 | 6.9 (5.8–8.0) | 0.60 (0.41–0.87) | 0.007 | 25.9 (21.7–30.1) | ||
  >  20 | 66 | 3.7 (2.8–4.6) |  |  | 15.6 (13.3–17.9) | ||
mCRPC-free survival, months | 0.51 (0.30–0.87) | 0.014 | |||||
  ≥ 18 | 53 | 6.9 (5.2–8.6) | 0.58 (0.40–0.85) | 0.005 | 23.6 (17.7–29.5) | ||
  <  18 | 77 | 3.2 (2.0–4.4) |  |  | 17.1 (15.1–19.1) | ||
Time to progression on A + P, months | 0.98 (0.58–1.65) | 0.930 | |||||
  ≥ 8 | 50 | 6.2 (4.5–7.9) | 0.75 (0.51–1.10) | 0.144 | 17.5 (15.3–19.7) | ||
  < 8 | 80 | 4.2 (2.6–5.8) |  |  | 19.0 (14.9–23.1) | ||
PSA response on A + P | 1.46 (0.86–2.46) | 0.161 | |||||
 Decline ≥50% | 72 | 4.9 (3.8–6.0) | 1.11 (0.75–1.62) | 0.608 | 17.4 (16.2–18.7) | ||
 Decline < 50% | 58 | 5.4 (3.6–7.2) |  |  | 28.3 (14.9–41.7) | ||